Compare Eli Lilly And Co (LLY) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs D Wave Quantum Inc — how do they compare? Eli Lilly And Co trades at $1,176.25 (market cap $1.04T), while D Wave Quantum Inc trades at $14.54 (market cap $5.54B). The key difference: Eli Lilly And Co is far larger — about 187.7× D Wave Quantum Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and D Wave Quantum Inc for 32 Days on average.
| LLY | QBTS | |
|---|---|---|
Market Cap | $1.04T | $5.54B |
Volume | 3,064,878 | 16,671,452 |
Sector | Health | Technology |
52-Week High | $1.28K | $44.78 |
52-Week Low | $799.57 | $12.98 |
Typical Hold Time | 93 Days | 32 Days |
Enterprise Value | $1.09T | $5.04B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
D-Wave Quantum (QBTS) trades at $14.52, down 4.6% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $355 million in 2025 on $25 million in revenue, with a deeply negative net income margin. However, all 13 analysts covering the stock maintain a Buy rating with a consensus price target of $34.38, suggesting significant upside potential from current levels.
The outlook is highly speculative, balancing substantial analyst optimism against severe financial losses and ongoing securities investigations. Investment opportunity hinges on the company's ability to commercialize quantum technology, but risks include cash burn, competitive pressures, and legal uncertainties that could impede shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
